… for Parkinson’s disease (PD) are urgently needed as the prevalence of the disease is increasing and no cure is … trials. Here, we use newly developed “AlphaLISA assays” to provide quantitative readouts of alpha-synuclein … controls and individuals with PD, DLB and MSA. We will then compare the diagnostic accuracy and clinical sensitivity …

… on the streets of New York City. I have never been able to imagine my life without a bicycle. For as long as I can … intentional. At twenty kilometers an hour, the landscape becomes your friend—every road offers a new perspective. I … to take part in an elite  mountain bike race in Morocco , where I was invited as a special participant. After …

… Study Rationale:  The scientific and clinical research community working on Parkinson’s disease (PD) is in need of biomarkers to facilitate the monitoring of disease progression and …  Our objective is to design more accurate assays and sample preparation protocols for measuring alpha-synuclein in CSF. …

… Today,  Deep Brain Stimulation  (DBS) is the most commonly … DBS in an area of the brain called the subthalamic nucleus (where DBS is usually concentrated still today) to treat PD …

… breakdown of food molecules in structures called mitochondria—is associated with an increased production in … can dampen neuroinflammation and improve the overall outcome of PD. Hypothesis: We hypothesize that by transiently … metabolic homeostasis and limiting neuroinflammation in a preclinical model of PD. These studies will test the …

… Mendel of Denver, Colorado, recalled travels as a couple: to Africa on safari and, most recently, to Mexico. But … there’s one journey their passports can’t document—living with Lee’s Parkinson’s disease and Lewy Body Dementia (LBD), … and lack of knowledge. Even within the Parkinson’s community, many have never heard of Lewy Body Dementia and …